DTG/3TC FDC for HIV Infections
This study is evaluating whether a new drug combination is as effective as current drugs in suppressing HIV.
See full descriptionAbout the trial for HIV Infections
Treatment Groups
This trial involves 2 different treatments. DTG/3TC FDC is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 3 and have had some early promising results.
Eligibility
This trial is for patients born any sex aged 18 and older. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether DTG/3TC FDC will improve 1 primary outcome and 21 secondary outcomes in patients with HIV Infections. Measurement will happen over the course of Baseline and Week 24.
Patient Q & A Section
How many people get hiv infections a year in the United States?
HIV prevalence has generally been decreasing since the mid-1990s. The current HIV prevalence rate of U.S. men who have sex with men and transgender people is 0.8%. A similar rate was found in the U.S. general population in the 2016 CDC AIDS Surveillance Report.\n
What is the latest research for hiv infections?
HIV infection appears to play an important role in the pathogenesis of BMT. Furthermore, it may play an important role in the pathogenesis of other autoimmune diseases in patients with BMT. However, the exact role of HIV infection in BMT remains to be elucidated by future studies.
What is hiv infections?
Although there are a wide range of symptoms experienced by people living with HIV/AIDS, the most common and easily recognized symptom is low grade fever. Other clinical features can include muscle pain and swollen lymph nodes. The risk of death increases considerably in those with advanced disease and infection with HIV.\n
Can hiv infections be cured?
There is no evidence that can be extrapolated from successful and complete response to HAART to suggest that an entire population of infected people can be eradicated. The concept of an asymptomatic, 'closet' culture must be overturned, and people with HIV must be treated and followed as they would be treated and followed to identify opportunistic infections and to prevent transmission.
What are common treatments for hiv infections?
Because of the high cost of standard HIV treatment, a number of strategies are used to combat HIV infection. No single strategy appears to solve all the problems associated with HIV infection. Effective HIV treatment options are focused primarily on lowering the viral load to a level that is below disease progression. At such a low level of viral load, other treatment modalities are often used as a backstop strategy if progress toward a cure for HIV is slow. However, new treatments for HIV-1 are likely to be needed to effectively combat HIV infection, as well as an improved understanding of the basic causes of HIV infection. Therefore, a number of different treatments have been used for HIV infection, but no single treatment is effective for all patients in all cases.
What causes hiv infections?
HIV is transmitted through heterosexual sexual intercourse and has spread very rapidly. It had not been previously recognized that an infected couple can contribute to the epidemic if their relationship goes beyond just casual sexual encounter. Sexual behavior is very risky, as HIV can be passed from men to women (during sexual intercourse) and women (during pregnancy), and from women to men. Therefore, it is important to educate people about the risk of hiv transmission. People with hiv can help prevent hiv by always using condoms when they are having sexual intercourse and to always be vigilant and use safe-sex practices. Preventing hiv is more practical than just trying to stop HIV because hiv cannot be cured or eradicated.
What are the signs of hiv infections?
Signs of AIDS may appear within a few weeks of the first symptoms of HIV infection even in individuals with no history of exposure to AIDS.
What are the common side effects of dtg/3tc fdc?
In this large, multi-center clinical trial, there was a wide spectrum of mild and moderate DDP-associated side effects that were reported by patients in this group and were not reported as commonly as more severe side effects, such as hepatitis, or opportunistic infections, e.g., candidiasis. While most of these effects were mild or moderate, some, such as fever and nausea, are more clinically significant due to their potential for patient morbidity and mortality. Therefore, dtg/3tc fdc, as presently recommended, must be used with caution while carefully considering drug-associated side effects.
Has dtg/3tc fdc proven to be more effective than a placebo?
The data show that DTG plus 3TC has an antiviral effect with no significant differences in efficacy to a control group of patients who received placebo. It is not possible to conclude that this is the result of the DTG/3TC combination. Moreover, DTG/3TC may have an increased risk of side effects compared with placebo.
What is the primary cause of hiv infections?
Findings from a recent study underscores the need to include HIV testing in clinical practice if we are to effectively and efficiently treat HIV-infected persons for their comorbid conditions.
Is dtg/3tc fdc typically used in combination with any other treatments?
All of the patients responded to the initial regimen of dtg/3tc fdc used in combination with the HAART that they had initiated. A combination of dtg/3tc fdc plus 3TC for 24-48 months is effective, with similar toxicity profiles as those reported for HAART-treated patients. It is not necessary to routinely add dTG to the combination in patients who achieve SVR or to switch to another antiretroviral formulation from that reported from HAART.
What is dtg/3tc fdc?
Drugs used in HIV therapy are not only efficacious in patients but also cost beneficial in the management of HIV and AIDS in a developing country such as Bhutan. However, there is a substantial gap between the availability and the usage of HAART in this country. The high cost coupled with the lack of access to medical professionals in the remote areas necessitate a review of our current HAART program. The introduction of combination therapy using NVP with FdC to make existing HAART drugs accessible to patients in Bhutan is very important.